

Gennady Bratslavsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9596555/publications.pdf>

Version: 2024-02-01

174
papers

3,847
citations

109321

35
h-index

149698

56
g-index

177
all docs

177
docs citations

177
times ranked

4904
citing authors

#	ARTICLE	IF	CITATIONS
1	Succinate Dehydrogenase Kidney Cancer: An Aggressive Example of the Warburg Effect in Cancer. <i>Journal of Urology</i> , 2012, 188, 2063-2071.	0.4	211
2	The Glycolytic Shift in Fumarate-Hydratase-Deficient Kidney Cancer Lowers AMPK Levels, Increases Anabolic Propensities and Lowers Cellular Iron Levels. <i>Cancer Cell</i> , 2011, 20, 315-327.	16.8	190
3	Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. <i>Lancet Oncology</i> , The, 2021, 22, 107-117.	10.7	172
4	Molecular Diagnosis and Therapy of Kidney Cancer. <i>Annual Review of Medicine</i> , 2010, 61, 329-343.	12.2	154
5	UOK 262 cell line, fumarate hydratase deficient (FH ^{-/-} /FH ^{-/-}) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. <i>Cancer Genetics and Cytogenetics</i> , 2010, 196, 45-55.	1.0	131
6	Asymmetric Hsp90 α N Domain SUMOylation Recruits Aha1 and ATP-Competitive Inhibitors. <i>Molecular Cell</i> , 2014, 53, 317-329.	9.7	101
7	Feasibility and Outcomes of Repeat Partial Nephrectomy. <i>Journal of Urology</i> , 2008, 180, 89-93.	0.4	94
8	Partial Adrenalectomy: Underused First Line Therapy for Small Adrenal Tumors. <i>Journal of Urology</i> , 2010, 184, 18-25.	0.4	85
9	Salvage Partial Nephrectomy for Hereditary Renal Cancer: Feasibility and Outcomes. <i>Journal of Urology</i> , 2008, 179, 67-70.	0.4	83
10	Renal Mass Biopsy: Always, Sometimes, or Never?. <i>European Urology</i> , 2016, 70, 403-406.	1.9	80
11	Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. <i>European Urology</i> , 2019, 76, 754-764.	1.9	80
12	Pseudohypoxic Pathways in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 4667-4671.	7.0	76
13	Robot-assisted laparoscopic partial nephrectomy for tumors greater than 4 cm and high nephrometry score: Feasibility, renal functional, and oncological outcomes with minimum 1 year follow-up. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 51-56.	1.6	73
14	Partial Nephrectomy After Previous Radio Frequency Ablation: The National Cancer Institute Experience. <i>Journal of Urology</i> , 2009, 182, 2158-2163.	0.4	66
15	Initial Experience With Robot Assisted Partial Nephrectomy for Multiple Renal Masses. <i>Journal of Urology</i> , 2009, 182, 1280-1286.	0.4	66
16	Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients. <i>EMBO Journal</i> , 2017, 36, 3650-3665.	7.8	64
17	The Surgical Approach to Multifocal Renal Cancers: Hereditary Syndromes, Ipsilateral Multifocality, and Bilateral Tumors. <i>Urologic Clinics of North America</i> , 2012, 39, 133-148.	1.8	63
18	Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. <i>JCO Precision Oncology</i> , 2019, 3, 1-23.	3.0	63

#	ARTICLE	IF	CITATIONS
19	Repeat Partial Nephrectomy on the Solitary Kidney: Surgical, Functional and Oncological Outcomes. <i>Journal of Urology</i> , 2010, 183, 1719-1724.	0.4	62
20	Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors. <i>Cell Reports</i> , 2016, 14, 872-884.	6.4	60
21	Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy. <i>Journal of Urology</i> , 2019, 201, 541-548.	0.4	57
22	The clinical implications of the genetics of renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 131-136.	1.6	56
23	The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. <i>Nature Communications</i> , 2016, 7, 12037.	12.8	56
24	A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. <i>Cancer Genetics</i> , 2012, 205, 377-390.	0.4	55
25	c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells. <i>Cell Reports</i> , 2015, 12, 1006-1018.	6.4	54
26	Co-chaperones TIMP2 and AHA1 Competitively Regulate Extracellular HSP90:Client MMP2 Activity and Matrix Proteolysis. <i>Cell Reports</i> , 2019, 28, 1894-1906.e6.	6.4	50
27	Results of the ADAPT Phase 3 Study of Rocabpudencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2327-2336.	7.0	49
28	Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling. <i>Cell Communication and Signaling</i> , 2019, 17, 120.	6.5	48
29	Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. <i>European Urology</i> , 2020, 77, 548-556.	1.9	41
30	Outcomes of Patients with Surgically Treated Bilateral Renal Masses and a Minimum of 10 Years of Followup. <i>Journal of Urology</i> , 2012, 188, 2084-2088.	0.4	40
31	Phosphorylation and Ubiquitination Regulate Protein Phosphatase 5 Activity and Its Prosurvival Role in Kidney Cancer. <i>Cell Reports</i> , 2017, 21, 1883-1895.	6.4	40
32	The metastatic potential of renal tumors: Influence of histologic subtypes on definition of small renal masses, risk stratification, and future active surveillance protocols. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 153.e15-153.e20.	1.6	39
33	Chemical Perturbation of Oncogenic Protein Folding: from the Prediction of Locally Unstable Structures to the Design of Disruptors of Hsp90 Client Interactions. <i>Chemistry - A European Journal</i> , 2020, 26, 9459-9465.	3.3	39
34	Oncological Outcomes of Partial Nephrectomy for Multifocal Renal Cell Carcinoma Greater Than 4 cm. <i>Journal of Urology</i> , 2010, 184, 59-63.	0.4	38
35	Post-translational Regulation of FNIP1 Creates a Rheostat for the Molecular Chaperone Hsp90. <i>Cell Reports</i> , 2019, 26, 1344-1356.e5.	6.4	38
36	Long-term management of bilateral, multifocal, recurrent renal carcinoma. <i>Nature Reviews Urology</i> , 2010, 7, 267-275.	3.8	36

#	ARTICLE	IF	CITATIONS
37	Primary urethral carcinoma: A Surveillance, Epidemiology, and End Results data analysis identifying predictors of cancer-specific survival. <i>Urology Annals</i> , 2018, 10, 170.	0.6	36
38	PET/CT imaging of renal cell carcinoma with 18F-VM4-037: a phase II pilot study. <i>Abdominal Radiology</i> , 2016, 41, 109-118.	2.1	35
39	Structural and functional regulation of lactate dehydrogenase-A in cancer. <i>Future Medicinal Chemistry</i> , 2020, 12, 439-455.	2.3	33
40	Structure and Function of the Nuclear Receptor Superfamily and Current Targeted Therapies of Prostate Cancer. <i>Cancers</i> , 2019, 11, 1852.	3.7	31
41	Targeting Hsp90 in urothelial carcinoma. <i>Oncotarget</i> , 2015, 6, 8454-8473.	1.8	31
42	Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy. <i>European Urology Focus</i> , 2020, 6, 122-130.	3.1	30
43	Extracellular Phosphorylation of TIMP-2 by Secreted c-Src Tyrosine Kinase Controls MMP-2 Activity. <i>IScience</i> , 2018, 1, 87-96.	4.1	29
44	Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors. <i>European Urology Focus</i> , 2019, 5, 748-755.	3.1	29
45	Robotic-assisted Radical Nephrectomy With Retrohepatic Vena Caval Tumor Thrombectomy (Level III) Combined With Extended Retroperitoneal Lymph Node Dissection. <i>Urology</i> , 2015, 86, 1235-1240.	1.0	28
46	Clinicopathologic Features of a Series of Primary Renal CIC-rearranged Sarcomas With Comprehensive Molecular Analysis. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1360-1369.	3.7	27
47	Predicting Occult Multifocality of Renal Cell Carcinoma. <i>European Urology</i> , 2010, 58, 118-126.	1.9	26
48	Feasibility and Outcomes of Partial Nephrectomy for Resection of at Least 20 Tumors in a Single Renal Unit. <i>Journal of Urology</i> , 2011, 185, 49-53.	0.4	26
49	Molecular mechanisms of tissue inhibitor of metalloproteinase 2 in the tumor microenvironment. <i>Molecular and Cellular Therapies</i> , 2014, 2, 17.	0.2	26
50	Repeat Robotic Partial Nephrectomy: Characteristics, Complications, and Renal Functional Outcomes. <i>Journal of Endourology</i> , 2016, 30, 1219-1226.	2.1	25
51	Association of Race With Cancer-Related Financial Toxicity. <i>JCO Oncology Practice</i> , 2022, 18, e271-e283.	2.9	23
52	Compared with radical nephrectomy, nephron-sparing surgery offers a long-term survival advantage in patients between the ages of 20 and 44 years with renal cell carcinomas (≥ 4 cm): An analysis of the SEER database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 549-554.	1.6	22
53	Genomic Features for Therapeutic Insights of Chemotherapy-Resistant, Primary Mediastinal Nonseminomatous Germ Cell Tumors and Comparison with Gonadal Counterpart. <i>Oncologist</i> , 2019, 24, e142-e145.	3.7	22
54	Familial Renal Cancer: Molecular Genetics and Surgical Management. <i>International Journal of Surgical Oncology</i> , 2011, 2011, 1-11.	0.6	21

#	ARTICLE	IF	CITATIONS
55	Pathological upstaging of clinical T1 renal cell carcinoma: an analysis of 115,835 patients from National Cancer Data Base, 2004–2013. <i>International Urology and Nephrology</i> , 2018, 50, 237-245.	1.4	21
56	Impact of Genetics on the Diagnosis and Treatment of Renal Cancer. <i>Current Urology Reports</i> , 2011, 12, 47-55.	2.2	20
57	The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 662-670.	8.2	19
58	Renal functional outcomes after robotic multiplex partial nephrectomy: the National Cancer Institute experience with robotic partial nephrectomy for 3 or more tumors in a single kidney. <i>International Urology and Nephrology</i> , 2016, 48, 1817-1821.	1.4	18
59	Are we underestimating the rates of incontinence after prostate cancer treatment? Results from NHANES. <i>International Urology and Nephrology</i> , 2017, 49, 1715-1721.	1.4	17
60	The Impact of Germline BHD Mutation on Histological Concordance and Clinical Treatment of Patients With Bilateral Renal Masses and Known Unilateral Oncocytoma. <i>Journal of Urology</i> , 2011, 185, 2050-2055.	0.4	16
61	Valproic Acid Alters Angiogenic and Trophic Gene Expression in Human Prostate Cancer Models. <i>Anticancer Research</i> , 2016, 36, 5079-5086.	1.1	16
62	Long-term Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma. <i>Urology</i> , 2020, 140, 85-90.	1.0	15
63	A specialized Hsp90 co-chaperone network regulates steroid hormone receptor response to ligand. <i>Cell Reports</i> , 2022, 40, 111039.	6.4	15
64	Renal Cell Carcinoma in Young Patients: a Review of Recent Literature. <i>Current Urology Reports</i> , 2015, 16, 1.	2.2	14
65	Chromophobe Renal Cell Carcinoma is the Most Common Nonclear Renal Cell Carcinoma in Young Women: Results from the SEER Database. <i>Journal of Urology</i> , 2016, 195, 847-851.	0.4	14
66	Should Preservable Parenchyma, and Not Tumor Size, Be the Main Determinant of the Feasibility of Partial Nephrectomy?. <i>Urology</i> , 2010, 76, 608-609.	1.0	13
67	Hereditary renal cell carcinoma: genetics, clinical features, and surgical considerations. <i>World Journal of Urology</i> , 2014, 32, 623-630.	2.2	13
68	Novel Concept and Method of Endoscopic Urethral Stricture Treatment Using Liquid Buccal Mucosal Graft. <i>Journal of Urology</i> , 2016, 196, 1788-1795.	0.4	13
69	A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 548-560.	1.6	13
70	Decreasing the indications for radical nephrectomy: a study of multifocal renal cell carcinoma. <i>Frontiers in Oncology</i> , 2012, 2, 84.	2.8	12
71	Comparison of survival for partial vs. radical nephrectomy in young patients with T1a renal cell carcinoma treated at commission on cancer-accredited facilities and influence of comorbidities on treatment choice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 660.e9-660.e15.	1.6	12
72	Fumarate hydratase as a therapeutic target in renal cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 923-936.	3.4	12

#	ARTICLE	IF	CITATIONS
73	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839.	7.0	12
74	Management of Locally Recurrent Kidney Cancer. <i>Current Urology Reports</i> , 2010, 11, 15-21.	2.2	11
75	Liquid buccal mucosa graft endoscopic urethroplasty: a validation animal study. <i>World Journal of Urology</i> , 2020, 38, 2139-2145.	2.2	11
76	Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer. <i>JAMA Oncology</i> , 2020, 6, 133.	7.1	11
77	Long term outcomes for patients with von Hippel-Lindau and Pheochromocytoma: defining the role of active surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 134.e1-134.e8.	1.6	11
78	Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 367.e1-367.e5.	1.6	11
79	Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. <i>Cancer</i> , 2021, 127, 3957-3966.	4.1	11
80	Sporadic renal angiomyolipoma in a patient with Birt-Hogg-DubÃ©: chaperones in pathogenesis. <i>Oncotarget</i> , 2018, 9, 22220-22229.	1.8	11
81	NF2 Tumor Suppressor Gene Inactivation in Advanced Papillary Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 716-718.	3.7	11
82	The dynamic interactome of human Aha1 upon Y223 phosphorylation. <i>Data in Brief</i> , 2015, 5, 752-755.	1.0	10
83	Renal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 182.e9-182.e15.	1.6	10
84	Reoperative Partial Nephrectomyâ€”Does Previous Surgical Footprint Impact Outcomes?. <i>Journal of Urology</i> , 2021, 206, 539-547.	0.4	10
85	Treatment trends, determinants, and survival of partial and radical nephrectomy for stage I renal cell carcinoma: results from the National Cancer Data Base, 2004â€”2013. <i>International Urology and Nephrology</i> , 2017, 49, 1375-1381.	1.4	10
86	Implications of High Rates of Metastatic Prostate Cancer in <i>BRCA2</i> Mutation Carriers. <i>Prostate</i> , 2016, 76, 1135-1145.	2.3	9
87	MMPs, tyrosine kinase signaling and extracellular matrix proteolysis in kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 316-321.	1.6	9
88	Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study. <i>Cancers</i> , 2021, 13, 3312.	3.7	9
89	Loss of Wave1 gene defines a subtype of lethal prostate cancer. <i>Oncotarget</i> , 2015, 6, 12383-12391.	1.8	9
90	Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma. <i>Nature Reviews Urology</i> , 2022, 19, 305-320.	3.8	9

#	ARTICLE	IF	CITATIONS
91	Applications of Focused Ultrasound in the Treatment of Genitourinary Cancers. <i>Cancers</i> , 2022, 14, 1536.	3.7	9
92	A comparison of outcomes for standard and multiplex partial nephrectomy in a solitary kidney: The National Cancer Institute experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 356.e1-356.e7.	1.6	8
93	Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. <i>European Urology</i> , 2022, 81, 223-228.	1.9	8
94	Argument in favor of performing partial nephrectomy for tumors greater than 7 cm: The metastatic prescription has already been written. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 829-832.	1.6	7
95	Pheochromocytoma in Urologic Practice. <i>European Urology Focus</i> , 2016, 1, 231-240.	3.1	7
96	Postoperative elevation in creatine kinase and its impact on renal function in patients undergoing complex partial nephrectomy. <i>International Urology and Nephrology</i> , 2016, 48, 1047-1053.	1.4	7
97	Surgical Techniques in the Management of Small Renal Masses. <i>Urologic Clinics of North America</i> , 2017, 44, 233-242.	1.8	7
98	Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 731.e1-731.e15.	1.6	7
99	AB11-based expression signature predicts breast cancer metastasis and survival. <i>Molecular Oncology</i> , 2022, 16, 2632-2657.	4.6	7
100	Preoperative cross-sectional imaging allows for avoidance of unnecessary adrenalectomy during RCC surgery. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 22.e23-22.e27.	1.6	6
101	The Role of Heat Shock Protein-90 in the Pathogenesis of Birt-Hogg-Dubé and Tuberous Sclerosis Complex Syndromes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 322-326.	1.6	6
102	Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies. <i>European Urology Oncology</i> , 2021, 4, 282-288.	5.4	6
103	X-Capsular Incision for Tumor Enucleation (X-CITE)-Technique: A Method to Maximize Renal Parenchymal Preservation for Completely Endophytic Renal Tumors. <i>Urology</i> , 2021, 154, 315-319.	1.0	6
104	NF2 mutation-driven renal cell carcinomas (RCC): A comprehensive genomic profiling (CGP) study. <i>Journal of Clinical Oncology</i> , 2020, 38, 726-726.	1.6	6
105	Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. <i>Cancer</i> , 2021, 127, 4557-4564.	4.1	5
106	E-cigarette use and the risk of bladder and lung cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 443-443.	1.6	5
107	Transrectal Ultrasound in Prostate Cancer: Current Utilization, Integration with mpMRI, HIFU and Other Emerging Applications. <i>Cancer Management and Research</i> , 2022, Volume 14, 1209-1228.	1.9	5
108	Differential Genetic Expression in Large Versus Small Clear Cell Renal Cell Carcinoma: Results from Microarray Analysis. <i>Journal of Cancer</i> , 2011, 2, 271-279.	2.5	4

#	ARTICLE	IF	CITATIONS
109	Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx. <i>Targeted Oncology</i> , 2019, 14, 33-38.	3.6	4
110	<i>PBRM1</i> mutation and immunotherapy efficacy: A comprehensive genomic profiling (CGP) assessment.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12091-12091.	1.6	4
111	Partial Adrenalectomy—Why Should it be Considered?. <i>Urology Practice</i> , 2015, 2, 359-366.	0.5	3
112	Reply to Patrick O. Richard, Micheal A.S. Jewett and Antonio Finelli's Letter to the Editor re: Alexander Kutikov, Marc C. Smaldone, Robert G. Uzzo, Miki Hafler, Gennady Bratslavsky, Bradley C. Leibovich. Renal Mass Biopsy: Always, Sometimes, or Never? <i>Eur Urol</i> 2016;70:403–6. <i>European Urology</i> , 2017, 71, e47-e48.	1.9	3
113	Phase II trial of vandetanib in Von Hippel-Lindau-associated renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4584-4584.	1.6	3
114	Clinical evaluation of 2-(18F) fluoro-2 deoxy-D-glucose PET/ CT in hereditary leiomyomatosis and renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 383-383.	1.6	3
115	The Changing Face of Renal-Cell Carcinoma. <i>Journal of Endourology</i> , 2010, 24, 753-757.	2.1	2
116	Surgical management of large renal tumors. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1889-1900.	2.4	2
117	Defining the radiobiology of prostate cancer progression: An important question in translational prostate cancer research. <i>Experimental Biology and Medicine</i> , 2014, 239, 805-812.	2.4	2
118	In Obese Patients, the Distance Between Skin and Renal Collecting System Changes with the Position of the Patient from Supine to Prone. <i>Journal of Endourology</i> , 2015, 29, 760-763.	2.1	2
119	Identification, Histological Characterization, and Dissection of Mouse Prostate Lobes for In Vitro 3D Spheroid Culture Models. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	2
120	Genomic landscape of <i>CDK12</i> mutated metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 165-165.	1.6	2
121	Clinically advanced penile (pSCC) and male urethral (uSCC) squamous cell carcinoma: A comparative genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2-2.	1.6	2
122	Sarcomatoid (srcRCC) versus clear cell (ccRCC) renal cell carcinoma: A comparative comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 349-349.	1.6	2
123	Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 2426.	3.7	2
124	The influence of race on financial toxicity among cancer patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1525-1525.	1.6	2
125	Surgical Insights for the Management of Variant Histology in Renal Cell Carcinoma. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021, 47, 935-942.	1.5	2
126	<i>PBRM1</i> genomic alterations in mesothelioma: Potential predictor of immunotherapy efficacy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8562-8562.	1.6	2

#	ARTICLE	IF	CITATIONS
127	Penile and uterine cervical squamous cell carcinomas: A comparative genomic profiling study.. Journal of Clinical Oncology, 2019, 37, 514-514.	1.6	2
128	Malignant pheochromocytoma: A comprehensive genomic profiling study.. Journal of Clinical Oncology, 2019, 37, 508-508.	1.6	2
129	Landscape of fibroblast growth factor receptor (<i>FGFR</i>) genomic alterations (GA) in urothelial bladder cancer (UBC).. Journal of Clinical Oncology, 2022, 40, 4568-4568.	1.6	2
130	Routine adrenalectomy in renal cancerâ€”an antiquated practice. Nature Reviews Urology, 2011, 8, 534-536.	3.8	1
131	An Unusual Etiology of Urinary Retention â€” Small Cell Prostate Carcinoma. Urology Case Reports, 2016, 7, 53-54.	0.3	1
132	A surgical â€œsewing machineâ€”for rapid graft quilting and suturing in challenging spaces. Urology Video Journal, 2020, 6, 100027.	0.2	1
133	Novel synthetic lethality (SL) anti-cancer drug target in urothelial bladder cancer (UCB) based on MTAP genomic loss: Incidence and correlations in standard of care (SOC).. Journal of Clinical Oncology, 2021, 39, 485-485.	1.6	1
134	The association between sexual orientation and screening of prevalent gender-specific cancers.. Journal of Clinical Oncology, 2021, 39, 198-198.	1.6	1
135	Genomic landscape of <i>MSH6</i>-mutated clinically advanced castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 5062-5062.	1.6	1
136	Clinically advanced pelvic squamous cell carcinomas (pSCC) in men and women: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2021, 39, 3130-3130.	1.6	1
137	The association of sexual orientation with cancer screening and diagnosis.. Journal of Clinical Oncology, 2021, 39, 6506-6506.	1.6	1
138	Prostate-specific Antigen Testing in Men with Disabilities: A Cross-sectional Analysis of the Health Information National Trends Survey. European Urology Focus, 2022, 8, 1125-1132.	3.1	1
139	Comprehensive genomic characterization of chemotherapy-resistant testicular germ cell tumors (TGCT).. Journal of Clinical Oncology, 2018, 36, 4555-4555.	1.6	1
140	Genomic features of metastatic testicular sex cord stromal tumors.. Journal of Clinical Oncology, 2019, 37, 532-532.	1.6	1
141	Extra-mammary Pagetâ€™s disease (EMPD) of the skin: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2019, 37, 9591-9591.	1.6	1
142	The emerging target <i>KRAS</i> G12C in genitourinary malignancies.. Journal of Clinical Oncology, 2020, 38, 434-434.	1.6	1
143	Association of <i>RB1</i> mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology, 2022, 40, 5063-5063.	1.6	1
144	Reply. Urology, 2015, 85, 291.	1.0	0

#	ARTICLE	IF	CITATIONS
145	A Festschrift in Honor of Edward M. Messing, MD, FACS. <i>Bladder Cancer</i> , 2018, 4, S1-S43.	0.4	0
146	HHV-8 positive clinically advanced castrate-resistant prostate cancer (mCRPC): A potentially distinct molecular subset.. <i>Journal of Clinical Oncology</i> , 2021, 39, 163-163.	1.6	0
147	Prostate-specific antigen testing in the disabled population: A cross-sectional analysis of the Health Information National Trends Survey (HINTS).. <i>Journal of Clinical Oncology</i> , 2021, 39, e17000-e17000.	1.6	0
148	Abstract 2470: Defining the reciprocal regulation of Abi1 and the androgen receptor in prostate cancer. , 2021, , .		0
149	The association of sexual orientation with prostate, breast, and cervical cancer screening and diagnosis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 129-129.	1.6	0
150	Association of partial nephrectomy with a long-term survival advantage in patients between age 20 and 44 with renal cell carcinomas \leq 4 cm: An analysis of the SEER database.. <i>Journal of Clinical Oncology</i> , 2013, 31, 408-408.	1.6	0
151	Comparison of histologic distribution of RCC in young and older patients: Results from the SEER database.. <i>Journal of Clinical Oncology</i> , 2013, 31, 419-419.	1.6	0
152	Abstract B06: Abi1 levels regulate prostate tumor progression in mice downstream from Pten inactivation. , 2014, , .		0
153	Minimally Invasive Radical Nephrectomy Including Vena Cava Thrombus. , 2018, , 63-71.		0
154	PD-L1 genomic alterations (GA) in solid tumors and hematologic malignancies: A comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12092-12092.	1.6	0
155	<i>FGFR3</i> Driven Metastatic Urothelial Carcinoma of the Urinary Bladder (mUCB): A Comprehensive Genomic Profiling Study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4531-4531.	1.6	0
156	Carcinomas of the renal medulla: A comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16586-e16586.	1.6	0
157	Primary sarcomas of the urinary bladder: A comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16530-e16530.	1.6	0
158	Differences in genomic signatures and opportunities for targeted and immunotherapy treatment between castrate-resistant <i>TMPRSS2:ERG</i> fusion-positive and -negative refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5061-5061.	1.6	0
159	Genomic findings in adenocarcinoma of the urinary bladder.. <i>Journal of Clinical Oncology</i> , 2019, 37, 132-132.	1.6	0
160	Abi1 loss drives prostate tumorigenesis through activation of EMT and noncanonical WNT signaling.. <i>Journal of Clinical Oncology</i> , 2019, 37, 280-280.	1.6	0
161	Expanding the use of targeted therapy for urothelial bladder cancer (UBC): Non- <i>FGFR3</i> receptor tyrosine kinase (RTK) gene rearrangements (ReAr) and fusions (fus).. <i>Journal of Clinical Oncology</i> , 2022, 40, 550-550.	1.6	0
162	The association of the use of anxiety and depression medications with PSA testing.. <i>Journal of Clinical Oncology</i> , 2022, 40, 56-56.	1.6	0

#	ARTICLE	IF	CITATIONS
163	Association of <i>RB1</i> mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology, 2022, 40, 156-156.	1.6	0
164	Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UBC) genomic alteration (GA) profile.. Journal of Clinical Oncology, 2022, 40, 563-563.	1.6	0
165	Genomic classification of clinically advanced major genito-urinary cancers (GUca) based on methylthioadenosine phosphorylase (<i>MTAP</i>) genomic loss.. Journal of Clinical Oncology, 2022, 40, 164-164.	1.6	0
166	Financial toxicity and its effect on screening for prostate and colon cancer.. Journal of Clinical Oncology, 2022, 40, 21-21.	1.6	0
167	Correlation of <i>AB11</i> and <i>PTEN</i> expression during prostate tumor progression.. Journal of Clinical Oncology, 2022, 40, 172-172.	1.6	0
168	Comparison of prostate specific antigen testing in men aged 55 to 69 with and without a history of cancer.. Journal of Clinical Oncology, 2022, 40, 230-230.	1.6	0
169	Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with clear cell RCC (ccRCC): Impact of <i>FLCN</i> genomic alteration (GA) status.. Journal of Clinical Oncology, 2022, 40, 292-292.	1.6	0
170	Robotic Assisted Caval Replacement for Recurrent Renal Cell Carcinoma Invading the Wall of the Inferior Vena Cava. Urology, 2022, 161, 131-134.	1.0	0
171	What is the impact of ischemic heart disease on PSA testing?. Journal of Clinical Oncology, 2022, 40, e17014-e17014.	1.6	0
172	The association of COVID-19 testing with cancer care disruption.. Journal of Clinical Oncology, 2022, 40, e18558-e18558.	1.6	0
173	Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with non-chromophobe RCC (nonchrRCC): Impact of <i>FLCN</i> genomic alteration (GA) status.. Journal of Clinical Oncology, 2022, 40, 4550-4550.	1.6	0
174	Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UCB) genomic alteration (GA) profile.. Journal of Clinical Oncology, 2022, 40, e16535-e16535.	1.6	0